Edwards Lifesciences Reports Fourth Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
Edwards Lifesciences (EW) PT Raised to $174 at Canaccord Genuity
February 2, 2018 7:08 AM ESTCanaccord Genuity raised its price target on Edwards Lifesciences (NYSE: EW) to $174.00 (from $140.00) while maintaining a Buy rating. An analysis suggests the stock should trade to at least $174 by year-end, based solely on the fundamentals currently evident in the business, let alone... More
Edwards Lifesciences (EW) Tops Q4 EPS by 3c; Raises Outlook
February 1, 2018 4:17 PM ESTEdwards Lifesciences (NYSE: EW) reported Q4 EPS of $0.94, $0.03 better than the analyst estimate of $0.91. Revenue for the quarter came in at $888.5 million versus the consensus estimate of $867.09 million.
GUIDANCE:
Edwards Lifesciences sees Q1 2018 EPS of $1.04-$1.14. Edwards Lifesciences sees Q1 2018... More



